• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • China innovative drug approvals – Technical requirements for pre-NDA meetings issued

China innovative drug approvals – Technical requirements for pre-NDA meetings issued

Monday, 20 December 2021 / Published in News, NMPA Registration in China, Pharmaceuticals & DMF

China innovative drug approvals – Technical requirements for pre-NDA meetings issued

China innovative drug approvals shall have pre-NDA meetings carried out at the beginning of the application process to address the common pharmacology issues.

On November 26, 2021, the CDE (Center for Drug Evaluation) under the NMPA (National Medical Products Administration) published (No.48-2021) the technical requirements for Pre-NDA meetings prior to innovative drugs going to market.

The Pre-NDA meeting is important to the approval of the NDA (New Drug Application) whilst focusing on key areas beneficial to the launch of new drug products, and providing applicants with ideas to improve the quality and efficiency of communication between applicants and the regulator.

The technical requirements addressed the following common issues:

  • API synthesis starting material selection
  • API pharmacological change research
  • API-related substances research and control
  • Research on mutagenic impurities
  • API quality control projects
  • Formulation change studies
  • Formulation degradation impurity research
  • Formulation quality control program and formulation dissolution
  • Release studies and other aspects of common pharmacy issues and general requirements

The technical requirement also stressed that major pharmacological changes should be completed as soon as possible before the start of clinical trials. If major pharmacological changes occur after the end of the clinical trial, the drug registration process may be affected.

In order to encourage the R&D and submission to accelerate the marketing process of innovative drugs, the NMPA supports applicants to resolve pharmacology-related issues during clinical trials through communication channels such as pre-application meeting for new drug clinical trials (Pre-IND meeting), end of phase II clinical trial for new drugs (EOP II)/pre-initiation meeting for phase III clinical trials (Pre-III meeting) at different research stages.

By Sun Jinlin and Jacky Li. Contact Cisema if you would like to learn more.

Tagged under: drugs, Innovative drugs, NDA, New Drug Applications, Pre-NDA

What you can read next

Plastic Microbeads to be banned from Daily Chemical Articles
China – CCC Certification Obligation Lifted for Numerous Products
China Medical Device Standards
December 2021 Regulatory Roundup for Medical Device Mandatory Standards

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Children cosmetics technical guidelines in China

    Children cosmetics technical guidelines in China – Newly issued by NIFDC

    Children cosmetics technical guidelines in Chin...
  • pH Determination Method

    China’s cosmetic safety technical specifications – 21 revision items issued

    China’s cosmetic safety technical specifi...
  • laser therapy devices

    Clinical evaluation of laser therapy devices – New guidelines issued

    Clinical evaluation of laser therapy devices ha...
  • dental implant system

    Clinical evaluation of dental implant systems in China – New guidelines issued

    Clinical evaluation of dental implant system ha...
  • China Medical Device Webinar

    China Medical Device Webinar with AdvaMed Accel for U.S. exporters

    The China Medical Device Webinar will be featur...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2003-2023 Cisema. All rights reserved.

TOP